TRENTON, N.J. (AP) - A cheaper version of Johnson & Johnson's top-selling drug, the rheumatoid arthritis treatment Remicade, could be available in the U.S. two years early after a federal judge ruled a key patent on the drug invalid.
J&J, based in New Brunswick, New Jersey, said Wednesday it plans to appeal the ruling.
Patent for J&J's Remicade invalidated, cheaper version looms
Aucun commentaire:
Enregistrer un commentaire